In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.
Magazine
We are pleased to announce the launch of UTIPRO® PLUS, our product for uncomplicated UTIs, in Finland.
The product is commercialized over the Finnish territory under the umbrella brand UrinCUR / Utipro plus and it is distributed by RFSU, our partner for the product on the Swedish and Norwegian territory as well.
For the fourth consecutive year, Noventure was present at the annual congress of the EAU - European Association of Urology- that took place in Barcelona 15th – 19th March 2019.
Noventure participation to EAU is to confirm its presence in the urology field with its medical device for oral use UTIPRO PLUS intended to control and prevent uncomplicated UTIs.
Noventure is proud to announce the launch of TASECTAN® in Croatia by its partner company JGL, under the brand Normia Stop.
TASECTAN® acts by forming a film which protects the intestinal mucosa, reducing the frequency and duration of diarrhea episodes in adults, children and infants.
TASECTAN® is marketed in 40 countries with growing sales of more than two million packs per year (ex-factory, as reported by commercial partners).
TASECTAN® is a class III medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments (CE 0373, Noventure SL).